Litcius/Paper detail

Ropeginterferon alfa-2b in hydroxyurea-intolerant or hydroxyurea-refractory essential thrombocythaemia (SURPASS ET): a multicentre, open-label, randomised, active-controlled, phase 3 study

Ruben A. Mesa, Harinder Gill, Lei Zhang, Jie Jin, Keita Kirito, Norio Komatsu, Albert Qin, Zhijian Xiao, Tsewang Tashi, Kazuya Shimoda, Kohshi Ohishi, Suning Chen, Xuelan Zuo, Shuichi Shirane, Yu Hu, Sujiang Zhang, Yi Wang, Katsuto Takenaka, Michiko Ichii, Na Xu, Lee-Yung Shih, Ken‐Hong Lim, Sung‐Eun Lee, Sung Hwa Bae, Winnie Z.Y. Teo, Dawn Maze, Stephen T. Oh, Prithviraj Bose, Toshiaki Sato, Oleh Zagrijtschuk, Sheena Lin, Weichung Joe Shih, John Mascarenhas, Lucia Masárová

2025The Lancet Haematology7 citationsDOIOpen Access PDF

Topics & Concepts

MedicinePhase (matter)Nuclear medicineInternal medicineClinical trialSurgeryPhases of clinical researchMEDLINERadiologyPathologyMyeloproliferative Neoplasms: Diagnosis and TreatmentPlatelet Disorders and TreatmentsHemophilia Treatment and Research
Ropeginterferon alfa-2b in hydroxyurea-intolerant or hydroxyurea-refractory essential thrombocythaemia (SURPASS ET): a multicentre, open-label, randomised, active-controlled, phase 3 study | Litcius